NCT06635954View on ClinicalTrials.gov

A Prospective Real World Evidence Study (PROWES) for Concordance Rate of Blood-based 3D Genome Conformation Mapping (Episwitch CiRT®) to Identify Likelihood of Response and Actual Response Rates to PD-(L)-1 Checkpoint Inhibitors Across Multiple Oncological Indications.

RecruitingOBSERVATIONAL
Enrollment

2,000

Participants

Timeline

Start Date

May 14, 2024

Primary Completion Date

May 14, 2026

Study Completion Date

May 14, 2027

Conditions
CancerImmunotherapyPD-1PD-L1Immune Checkpoint Therapy
Trial Locations (3)

29732

RECRUITING

Carolina Blood and Cancer Care Associates, Rock Hill

31021

RECRUITING

Cancer Center of Middle Georgia, Dublin

06360

RECRUITING

Eastern Connecticut Hematology and Oncology, Norwich

Sponsors
All Listed Sponsors
collaborator

Community Clinical Oncology Research Network, LLC

UNKNOWN

lead

Oxford Biodynamics Inc.

INDUSTRY

NCT06635954 - A Prospective Real World Evidence Study (PROWES) for Concordance Rate of Blood-based 3D Genome Conformation Mapping (Episwitch CiRT®) to Identify Likelihood of Response and Actual Response Rates to PD-(L)-1 Checkpoint Inhibitors Across Multiple Oncological Indications. | Biotech Hunter | Biotech Hunter